The Trump administration plans to launch a five-year pilot program that would allow Medicare and Medicaid to cover high-demand weight loss drugs.
The proposed pilot would open the door for coverage of GLP-1 medications such as Wegovy, Ozempic, Zepbound, and Mounjaro—currently priced between $5,000 and $7,000 per year. While Medicare currently bars coverage of these drugs when prescribed solely for obesity, the pilot aims to change that.
Timeline and rollout
- Medicaid coverage could begin as early as April 2026
- Medicare coverage would follow in January 2027
If implemented, the pilot would mark a significant policy shift. The Trump administration earlier rejected a similar proposal from the Biden administration, citing cost concerns.
Why this matters
More than 135 million Americans rely on Medicare and Medicaid. Currently:
- Medicaid covers weight-loss drugs in 13 states, usually when prescribed for conditions like diabetes or sleep apnea
- Medicare prohibits coverage for weight-loss-only use
This pilot would give state Medicaid programs and Medicare Part D plans the option to cover GLP-1 drugs for obesity treatment—whether or not the patient has a secondary health condition.
What the industry is saying
Pharmaceutical giants Novo Nordisk and Eli Lilly, the makers of the medications in question, have remained tight-lipped about the proposal. However, a Lilly spokesperson reiterated the company’s goal:
“We’re committed to working with payers and policymakers to expand coverage and improve access.”
Market analysts estimate the GLP-1 drug market could exceed $150 billion within the next decade. Following the announcement:
- Lilly stock rose 2%
- Novo shares climbed 1.2%
- Hims & Hers Health—which offers low-cost compounded alternatives—fell 6% as investors anticipate competition from public plans
Internal divide?
The pilot may expose philosophical differences within the administration. CMS Director Mehmet Oz, a vocal advocate of GLP-1 drugs, supports broader access. Meanwhile, Health Secretary Robert F. Kennedy Jr. has questioned their affordability and warned against overreliance on medication over lifestyle change.
Will coverage help reduce obesity?
GLP-1 drugs help patients lose 15–20% of their body weight on average. Public health experts say broader coverage could:
- Make obesity care more equitable
- Lower long-term costs tied to heart disease, diabetes, and stroke
- Reduce stigma around medical treatment for obesity
Still, critics warn that a massive expansion in coverage could strain federal and state budgets, especially if demand explodes.
This content is brought to you by the FingerLakes1.com Team. Support our mission by visiting www.patreon.com/fl1 or learn how you send us your local content here.